H
Howard N. Hodis
Researcher at University of Southern California
Publications - 318
Citations - 24700
Howard N. Hodis is an academic researcher from University of Southern California. The author has contributed to research in topics: Menopause & Intima-media thickness. The author has an hindex of 74, co-authored 297 publications receiving 22233 citations. Previous affiliations of Howard N. Hodis include Oklahoma Medical Research Foundation.
Papers
More filters
Journal ArticleDOI
Preservation of Pancreatic Beta-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women
Thomas A. Buchanan,Anny H. Xiang,Ruth Peters,Siri L. Kjos,Aura Marroquin,Jose Goico,Cesar Ochoa,Sylvia Tan,Kathleen Berkowitz,Howard N. Hodis,Stanley P. Azen +10 more
TL;DR: Protection from diabetes in the troglitazone group was closely related to the degree of reduction in endogenous insulin requirements 3 months after randomization and persisted 8 months after study medications were stopped, and was associated with preservation of beta-cell compensation for insulin resistance.
Journal ArticleDOI
The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events
Howard N. Hodis,Wendy J. Mack,Laurie LaBree,Robert H. Selzer,Chao-ran Liu,Ci-hua Liu,Stanley P. Azen +6 more
TL;DR: This long-term follow-up of the Cholesterol Lowering Atherosclerosis Study cohort indicated that progression of coronary artery disease was predictive of coronary events, and the objective was to determine whether carotid arterial intima-media thickness predicts coronary events.
Journal ArticleDOI
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
Shalender Bhasin,Juan P. Brito,Glenn R. Cunningham,Frances J. Hayes,Howard N. Hodis,Alvin M. Matsumoto,Peter J. Snyder,Ronald S. Swerdloff,Frederick C. W. Wu,Maria A Yialamas +9 more
TL;DR: It is suggested that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost.
Journal ArticleDOI
The 2017 hormone therapy position statement of The North American Menopause Society.
JoAnn V. Pinkerton,Fernando Sánchez Aguirre,Jennifer Blake,Felicia Cosman,Howard N. Hodis,Susan Hoffstetter,Andrew M. Kaunitz,Sheryl A. Kingsberg,Pauline M. Maki,JoAnn E. Manson,Polly Marchbanks,Michael R. McClung,Lila E. Nachtigall,Lawrence M. Nelson,Diane Todd Pace,Robert L. Reid,Phillip M. Sarrel,Jan L. Shifren,Cynthia A. Stuenkel,Wulf H. Utian +19 more
TL;DR: Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture.
Journal ArticleDOI
Ambient air pollution and atherosclerosis in Los Angeles.
Nino Künzli,Michael Jerrett,Wendy J. Mack,Bernardo Beckerman,Laurie LaBree,Frank D. Gilliland,Duncan C. Thomas,John M. Peters,Howard N. Hodis +8 more
TL;DR: These results represent the first epidemiologic evidence of an association between atherosclerosis and ambient air pollution and given the leading role of cardiovascular disease as a cause of death and the large populations exposed to ambient PM2.5, these findings may be important and need further confirmation.